Vivus BV, a subsidiary of Vivus LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious medical conditions and life-limiting diseases, announced the new pricing structure of QSIVA hard modified-release capsules phentermine/topiramate is available as of February in Iceland. The new pricing structure is made available as of February for 566.13 ISK per day at pharmacies throughout Iceland. QSIVA offers competitive pricing on a price-per-kilogram basis across the approved European countries.
In clinical studies, QSIVA has demonstrated clinically meaningful and sustained weight loss when combined with diet and exercise. Additional clinical research has shown that QSIVA, when used in combination with digital lifestyle intervention, was associated with greater weight loss and improvements in cardiovascular risk measures compared with lifestyle intervention alone. Globally, obesity and overweight pose significant public health challenges, impacting millions of people across Europe.
These conditions increase the risk of various health problems, making them leading causes of death like heart disease, stroke, and diabetes. Patients urgently require effective treatments to enhance their quality of life. In conjunction with a healthy lifestyle, QSIVA can assist patients in achieving and maintaining healthy weight goals, thereby significantly reducing the associated health risks.
QSIVA is currently available in Sweden, Denmark, Finland, Iceland, and Poland with more countries coming in the future. QSIVA (the European brand name for QSYMIA) is approved in Sweden, Denmark, Finland, Iceland, and Poland. QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of QSIVA on reducing cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations, have not been established. QSIVA hard modified-release capsules phentermine/topiramate is contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); in patients with hypersensitivity to sympathomimetic amines, to the active substances, or to any of the excipients in QSIVA.
QSIVA can cause foetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use highly effective contraception while taking QSIVA. If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should consult promptly with their doctor.
The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, depression, constipation, and dry mouth.
